Who Paid My Doc
Aristada
Drug Cns
NDC 65757-402-03
General payments
$25,885,812
Research payments
$5,612,142
Through program year 2025, $25,885,812 in general payments and $5,612,142 in research payments were reported against Aristada (Cns).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $2,847,827 | 76,155 |
| 2025 | Research | $324,430 | 1 |
| 2024 | General | $2,203,823 | 56,506 |
| 2024 | Research | $315,467 | 1 |
| 2023 | General | $3,776,118 | 62,519 |
| 2023 | Research | $1,326,932 | 19 |
| 2022 | General | $2,849,626 | 53,690 |
| 2022 | Research | $599,841 | 6 |
| 2021 | General | $3,827,090 | 38,430 |
| 2021 | Research | $338,989 | 7 |
| 2020 | General | $2,426,705 | 11,490 |
| 2020 | Research | $430,811 | 5 |
| 2019 | General | $7,954,623 | 29,642 |
| 2019 | Research | $2,275,672 | 181 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 115 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 53 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
328,432 general · 220 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.